NEW YORK (GenomeWeb) — The Translational Genomics Research Institute and Northern Arizona University have been jointly awarded a US patent for an allele-specific, real-time PCR-based assay to detect H1N1 pandemic flu and resistance to antiviral treatments.
DxNA, a privately owned St. George, Utah-based molecular diagnostics firm, will acquire privately held Flagstaff, Ariz.-based Pathogene for an undisclosed amount under an agreement inked by the companies this week.
NEW YORK (GenomeWeb News) – Molecular diagnostics shop DxNA has signed a letter of intent to acquire PCR-based assay development company PathoGene, the companies said this week.
DxNA has acquired exclusive rights to run PathoGene's multiplexed Staphylococcus MRSA+ assay on DxNA's real-time PCR-based GeneStat platform, the companies said this week.
DxNA has been awarded US Patent No. 8,169,122, "Ultrasonic release of DNA or RNA."
Danvern Roberts, William Bickmore, Jared Hummel, Daniel Esplin, and Paul Day are named as inventors on the patent.
DxNA of St. George, Utah, has been awarded US Patent No. 7,993,910, "Methods and apparatus for amplification of DNA using sonic energy."
William Bickmore and Danvern Ray Roberts are named as inventors on the patent.
CNN reports that a US Food and Drug Administration document says Johnson & Johnson's SARS-CoV-2 vaccine meets the requirements to receive an Emergency Use Authorization.
In Cell this week: analysis of fitness patterns among SARS-CoV-2 isolates, single-cell transcriptome analysis of immune features in COVID-19, and more.
